Identification of Diabetic Small-Fiber Neuropathy Based on Electrophysiological and Psychophysical Responses to Intra-Epidermal Electric Stimulation using a Naïve Bayes Classifier.

Diagnosis and stratification of small-fiber neuropathy patients is difficult due to a lack of methods that are both sensitive and specific. Our lab recently developed a method to accurately measure psychophysical and electrophysiological responses to intra-epidermal electric stimulation, specifically targeting small nerve fibers in the skin. In this work, we study whether using one or a combination of psychophysical and electrophysiological outcome measures can be used to identify diabetic small-fiber neuropathy. It was found that classification of small-fiber neuropathy based on psychophysical and electrophysiological responses to intra-epidermal electric stimulation could match or even outperform current state-of-the-art methods for the diagnosis of small-fiber neuropathy.Clinical Relevance-Neuropathy is damage or dysfunction of nerves in the skin, often leading to the development of chronic pain. Small-fiber neuropathy is the most prevalent type of neuropathy and occurs frequently in patients with diabetes mellitus, but can also occur in other diseases or in response to chemotherapy. Early detection of neuropathy could help diabetic patients to adapt glucose management, and doctors to adjust treatment strategies to prevent nerve loss and chronic pain, but is impeded by a lack of clinical tools to monitor small nerve fiber function.

Exploring Psychophysical and Neurophysiological Responses to Intra-Epidermal Electrical Stimuli in Patients With Persistent Spinal Pain Syndrome Type 2 with a Spinal Cord Stimulator.

There is a lack of measures that provide insights into how spinal cord stimulation (SCS) modulates nociceptive function in patients with persistent spinal pain syndrome type 2 (PSPS-T2). Recently, we observed altered nociceptive detection thresholds (NDTs) in response to intra-epidermal electrical stimulation (IES) on the feet of PSPS-T2 patients when dorsal root ganglion stimulation was turned on. Furthermore, we observed altered NDTs and evoked potentials (EPs) in response to IES on the hands of PSPS-T2 patients. To explore whether EPs were obstructed by SCS artifacts, we applied IES twice to the hands of patients with SCS turned on (SCS-ON/ON group). To explore possible confounding effects of SCS outside the stimulated area, we repeated IES on the hands of these patients, once with SCS turned off and subsequently once with SCS turned on (SCS-OFF/ON group). The results demonstrated that EPs were not obstructed by SCS artifacts. Additionally, NDTs and EPs did not significantly change between measurements in the SCS-ON/ON and the SCS-OFF/ON groups. Therefore, the results suggested that possible confounding effects of SCS outside the nociceptive system did not interfere with the detection task performance. This work warrants further exploration of NDT-EP phenomena in response to IES at the painful feet of patients.Clinical Relevance-This work contributes to developing a clinical tool to explore psychophysical and neurophysiological biomarkers for observing modulating effects of SCS in patients with PSPS-T2.

First Report on Real-World Outcomes with Evoked Compound Action Potential (ECAP)-Controlled Closed-Loop Spinal Cord Stimulation for Treatment of Chronic Pain.

INTRODUCTION: A novel closed-loop spinal cord stimulation (SCS) system has recently been approved for use which records evoked compound action potentials (ECAPs) from the spinal cord and utilizes these recordings to automatically adjust the stimulation strength in real time. It automatically compensates for fluctuations in distance between the epidural leads and the spinal cord by maintaining the neural response (ECAP) at a determined target level. This data collection was principally designed to evaluate the performance of this first closed-loop SCS system in a 'real-world' setting under normal conditions of use in a single European center. METHODS: In this prospective, single-center observational data collection, 22 patients were recruited at the outpatient pain clinic of the St. Antonius Hospital. All candidates were suffering from chronic pain in the trunk and/or limbs due to PSPS type 2 (persistent spinal pain syndrome). As standard of care, follow-up visits were completed at 3 months, 6 months, and 12 months post-device activation. Patient-reported outcome data (pain intensity, patient satisfaction) and electrophysiological and device data (ECAP amplitude, conduction velocity, current output, pulse width, frequency, usage), and patient interaction with their controller were collected at baseline and during standard of care follow-up visits. RESULTS: Significant decreases in pain intensity for overall back or leg pain scores (verbal numerical rating score = VNRS) were observed between baseline [mean ± SEM (standard error of the mean); n = 22; 8.4 ± 0.2)], 3 months (n = 12; 1.9 ± 0.5), 6 months (n = 16; 2.6 ± 0.5), and 12 months (n = 20; 2.0 ± 0.5), with 85.0% of the patients being satisfied at 12 months. Additionally, no significant differences in average pain relief at 3 months and 12 months between the real-world data (77.2%; 76.8%) and the AVALON (71.2%; 73.6%) and EVOKE (78.1%; 76.7%) studies were observed. CONCLUSIONS: These initial 'real-world' data on ECAP-controlled, closed-loop SCS in a real-world clinical setting appear to be promising, as they provide novel insights of the beneficial effect of ECAP-controlled, closed-loop SCS in a real-world setting. The presented results demonstrate a noteworthy maintenance of pain relief over 12 months and corroborate the outcomes observed in the AVALON prospective, multicenter, single-arm study and the EVOKE double-blind, multicenter, randomized controlled trial. TRIAL REGISTRATION: The data collection is registered on the International Clinical Trials Registry Platform (Trial NL7889).

Combining Psychophysical and EEG Biomarkers for Improved Observation of Altered Nociceptive Processing in Failed Back Surgery Syndrome.

Diagnosis and stratification of chronic pain patients is difficult due to a lack of sensitive biomarkers for altered nociceptive and pain processing. Recent developments enabled to preferentially stimulate epidermal nerve fibers and simultaneously quantify the psychophysical detection probability and neurophysiological EEG responses. In this work, we study whether using one or a combination of both outcome measures could aid in the observation of altered nociceptive processing in chronic pain. A set of features was extracted from data from a total of 66 measurements on 16 failed back surgery syndrome patients and 17 healthy controls. We assessed how well each feature discriminates both groups. Subsequently, we used a random forest classifier to study whether psychophysical features, EEG features or a combination can improve the classification accuracy. It was found that a classification accuracy of 0.77 can be achieved with psychophysical features, while a classification accuracy of 0.65 was achieved using only EEG features.Clinical Relevance-This study shows which combined features of nociceptive detection behavior and evoked EEG responses are most sensitive and specific to altered nociception in failed back surgery syndrome.

Exploring Nociceptive Detection Thresholds Combined with Evoked Potentials in Patients with Diabetes Mellitus.

There is a lack of diagnostic tools that can objectively measure small fiber neuropathy (SFN) in patients with diabetes mellitus (DM). Recently, nociceptive nerve function was observed by nociceptive detection thresholds (NDTs) and brain evoked potentials (EPs) during intra-epidermal electrical stimulation (IES) targeting Aδ-fibers. In this proof of principle, we studied whether it is possible to measure NDTs combined with EPs in DM patients with and without neuropathic pain. Furthermore, we explored the sensitivity of NDTs and EPs for polyneuropathy in these patients. Five DM patients diagnosed with painful neuropathy (DMp), five DM patients without painful neuropathy (DM), and five healthy controls (HC) were analyzed. These preliminary results showed that we can accurately measure NDTs and EPs in patients with diabetes. Strikingly, increased NDTs were found in DM and DMp compared to HC, of which the DMp showed the largest NDTs. This suggests that NDTs during IES could be a powerful biomarker for monitoring peripheral dysfunctions. Current EEG data of patients did not show any significant differences. The population needs to be enlarged before we can investigate the sensitivity of these NDTs and EPs to diabetic polyneuropathy and associated changes in nociceptive processing in more detail.Clinical Relevance- This proof of principle in a small group of patients with diabetes mellitus potentially treats the observation of the loss of nociceptive function occurring with small fiber neuropathy. That helps the development of a diagnostic measure to monitor future (early-stage) nociceptive dysfunctions in a clinical environment.

Combined Evaluation of Nociceptive Detection Thresholds and Evoked Potentials during Conditioned Pain Modulation: A Feasibility Study.

Deficient top-down inhibitory control via diffuse noxious inhibitory control (DNIC) is a mechanism known to be responsible for the maintenance and development in several chronic pain syndromes. Experimentally, DNIC is often induced by conditioned pain modulation (CPM) paradigms such as a Cold Pressor Test (CPT). Recently, a method called the NDT-EP method has been developed with the aim to evaluate the nociceptive function, which it does via simultaneous tracking of nociceptive detection thresholds (NDT) and evoked potentials (EP). It remains to be investigated whether we can evaluate DNIC via the NDT-EP method. In this study, we take the first step to investigate this by evaluating the feasibility to combine the NDT-EP method with a 7 minutes CPT. In total 20 participants of a wide age-range were measured before, during, and after a CPT. All except 1 participant were able to complete the protocol, and enough stimulus-response pairs could be obtained for psychophysical as well as electrophysiological evaluation. Preliminary analysis of the NDT's and EP's showed results in line with earlier research such as a higher threshold for nociceptive stimuli and a lower EP amplitudes. Several NDT's of mostly elderly people (59±16 years), however, exceeded the maximum applicable stimulus strength during (7/20) or after (9/20) CPT and consequently had to be excluded from the analysis. To what extent this is a consequence of the CPT or other factors such as strong habituation associated more with elderly people, is subject to further investigation. In conclusion, the results of this study show that with the present protocol, it is feasible to combine the NDT-EP method with a CPM paradigm in almost all subjects, but that the NDT data of mostly older subjects could not be properly analyzed. Further directions for research and improvements are outlined.

A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary.

BACKGROUND AND PURPOSE: The goal of this study was to determine the prevalence and incidence of neuromyelitis optica spectrum disorder (NMOSD) in Hungary based on the 2015 International Panel of NMO Diagnosis (IPND) criteria. METHODS: A retrospective population-based cohort study was conducted of 6.4 million Hungarians (age ≥ 16 years) between 1 January 2006 and 31 December 2016. Possible NMOSD patients were selected via multistage re-evaluation from multiple sources. Crude and sex- and serostatus-specific prevalence (per 100 000 persons) and incidence rates (per 1 000 000 person-years) from 2006 to 2015 were estimated and age-adjusted rates were determined. RESULTS: Of 2262 study candidates, 154 NMOSD patients (age ≥ 16 years) with onset until 31 December 2016 were identified based on 2015 IPND criteria. The prevalence analysis on 1 January 2016 included 123 NMOSD living cases, resulting in a prevalence of 1.91 [95% confidence interval (CI) 1.52-2.28] per 100 000 persons. The 101 incident cases emerging from the observed 76 394 288 person-years provided an incidence rate of 1.32 (95% CI 1.08-1.61) per 1 000 000 person-years. Age-adjusted prevalence was 1.87 (95% CI 1.56-2.23) per 100 000 persons and incidence was 1.20 (95% CI 0.98-1.46) per 1 000 000 person-years. CONCLUSIONS: In this first report of a large population-based epidemiological study from an Eastern European Caucasian population using robust case validation, a greater prevalence and incidence of NMOSD was found compared to previous large studies in Caucasian populations.

[Acute arteria mesenterica superior syndrome caused by severe electric injury]. / Akut arteria mesenterica superior szindróma súlyos elektrotrauma után

The case of acute arteria mesenterica superior syndrome--occurred in a boy aged 10, as rare complication of high voltage electro-trauma--is reported. The aetiology of the syndrome, as well as a possible new pathogenic factor are discussed. The clinical picture and the therapeutic principles are dealt with.